In acute Plasmodium falciparum (P. falciparum) malaria, the pro-and anti-inflammatory immune pathways must be delicately balanced so that the parasitemia is controlled without inducing immunopathology. An important mechanism to fine-tune T cell responses in the periphery is the induction of coinhibitory receptors such as CTLA4 and PD1. However, their role in acute infections such as P. falciparum malaria remains poorly understood. 
were obtained from patients with acute P. falciparum malaria treated in Germany. Flow cytometric analysis showed a more frequent expression of CTLA4 and PD1 on CD4 + T cells of malaria patients than of healthy control subjects. In vitro stimulation with P. falciparum-infected red blood cells revealed a distinct population of PD1 
Author Summary
In acute infections like malaria, our immune systems must achieve a careful balance between inflammatory and anti-inflammatory responses to successfully fight the infection without causing harm to the host. In this study, we examined the CD4 + T cell response and CD4 + T cell regulation in patients with acute malaria. Important mechanisms to
Introduction
Malaria remains one of the leading health burdens worldwide with about 600 000 deaths per year. Most of these deaths are attributable to the species Plasmodium falciparum (P. falciparum) [1] . Primary infection with P. falciparum initially induces a strong Th1-type CD4 + T cell response. While a strong proinflammatory Th1 response can contribute to control of parasitemia and protection to subsequent infections [2, 3] , it can also be pathological as it activates the endothelium and thereby promotes sequestration of parasitized red blood cells in the microvessels of vital organs such as the brain [4, 5] . This impedes parasite clearance by the spleen and enhances severe manifestations of malaria such as cerebral malaria [6] [7] [8] . Therefore, a tight coordination of the immune response is needed to ensure the optimal outcome for the patient. Strong proinflammatory responses activate counteracting pathways such as the induction of regulatory T cell (T reg ) populations and the production of anti-inflammatory cytokines, which both are crucial for preventing immunopathology in malaria and other parasitic diseases [9] [10] [11] [12] . Another key mechanism that regulates potentially immunopathological T cell responses in the periphery is the induction of coinhibitory receptors such as cytotoxic T-Lymphocyte attenuator 4 (CTLA4) and programmed death 1 (PD1) on T cells. The importance of PD1 and CTLA4 in T cell regulation has largely been studied in various chronic viral diseases, including HIV, hepatitis B, and hepatitis C. Such chronic viral diseases induce sustained PD1 and CTLA4 expression on activated T cells. This is associated with T cell exhaustion and reduced effector functions of the cells. Blockade of these receptors can partially rescue the T cell responses to these viruses, thereby reducing the viral burden [13] [14] [15] [16] [17] . Several recent studies, however, suggest that coinhibitory receptors inhibit T effector functions not only in chronic viral but also in acute infections [18] [19] [20] [21] [22] . In support of this, we and other groups have shown that in experimental murine malaria, conventional T cells strongly express the coinhibitory receptors CTLA4 and PD1 [18, 23] . Blocking coinhibitory receptors improves parasite control [20, 24, 25] but also leads to more severe manifestations of disease in several models of experimental malaria [18, 20, 23] . Recent studies reported that CTLA4 and PD1 are also upregulated on the T cells of patients with acute malaria or children that are regularly exposed to P. falciparum in endemic areas [24, [26] [27] [28] . However, it remains unclear how the expression of these coinhibitory receptors influences the immune response to acute P. falciparum infection in humans.
We evaluated the CD4 + T cell response in patients with acute imported malaria in Hamburg, Germany to investigate whether the induction of coinhibitory receptors downregulates the T cell response in acute P. falciparum malaria and to further elucidate involved regulatory pathways. Fig 1A and 1B) . The majority of PD1-expressing CD4 + T cells also coexpressed CTLA4 (Fig 1A and 1B) . Pearson correlation analysis showed that the PD1 expression correlated strongly with CTLA4 expression on CD4 + T cells (r = 0.83; Fig 1C) in malaria patients. The expression of CTLA4 and PD1 was transient and dropped after treatment completion and parasite clearance (Fig 1D) . There was no correlation between the expression of CTLA4 or PD1 on CD4 + T cells and levels of parasitemia of the patient before treatment was initiated ( Fig 1E) . CTLA4 and PD1 expression on CD4 + T cells were also compared between patients with an uncomplicated course of malaria (n = 13) and patients with severe cerebral malaria (n = 3). The percentage of CTLA4 + CD4 + T cell was significantly higher in patients with cerebral malaria than in patients with uncomplicated malaria (Fig 1F) . There was a trend towards a more frequent expression of PD1 on CD4 + T cells in patients with severe cerebral malaria ( Fig 1F) . Additionally, we analyzed cytokine concentrations in PBMC culture supernatants after 5 days of stimulation with iRBC and assessed how a blockade of CTLA4 and PD1 influenced P. falciparum-specific cytokine production. Consistent with our flow cytometry results, IFNγ and IL10 were detected in most culture supernatants. Of the 9 patients who were tested, 8 showed P. falciparum-specific IFNγ production (mean 540 pg/ml, range 30-1477 pg/ml) and 7 showed detectable IL10 production (mean 108 pg/ml, range 30-359 pg/ml). Adding blocking antibodies against CTLA4 and PDL1 strongly enhanced P. falciparum-specific IFNγ production in all 9 patients who were tested and led to an average 4.5-fold increase of the IFNγ-concentration. The effect on IL10 was less striking with a mean 1.7 fold increase of IL10 concentrations when adding anti-PDL1 and -CTLA4 (Fig 3C) . One representative patient out of 11 is shown. C) PBMC were stimulated for 120hrs with iRBC and with/without addition of blocking antibodies against CTLA4 and PDL1. IL10 and IFNγ were measured in culture supernatants by ELISA. Fold-increase of cytokine production was calculated by dividing the net iRBC-specific cytokine production with blockade of CTLA4/PDL1 by net-cytokine production without antibody blockade. P = 0.004 (IFNγ) and P = 0.016 (IL10), using the Wilcoxon matched pairs test on net-cytokine concentration results. + T Cells in Malaria co-stimulatory CD28 for shared ligands [31] and downregulation of cell effector functions upon ligation [32] . However, both receptors, CTLA4 and PD1, have also been associated with regulatory T cell populations [33] . We therefore asked whether the malaria-induced PD1 
Discussion
The present study explored the role of coinhibitory receptors as an immune regulatory pathway in acute P. falciparum malaria. We initially hypothesized that the induction of coinhibitory + T eff cells therefore constitute a distinct regulatory T cell population which is induced during acute malaria. Our collection of blood from adult patients with imported P. falciparum malaria in Hamburg, Germany, enabled us to conduct complex functional experiments in the setting of acute infection and disease that would not be possible in holoendemic areas, where adults rarely develop acute febrile malaria and only small amounts of blood can be collected from sick children. Our patient cohort consisted largely of two groups, namely, Caucasian patients who had malaria for the first time, and patients of West African descent who reside in Germany and whose last treatment for malaria was at least 5 years before the index infection (S1 Table) . Notably, we did not observe a difference between the two main groups of our patient cohort in terms of their T cell phenotypes and regulatory function (S12 Fig). Recently, several studies have observed that patients with acute malaria, and children in endemic regions, who are exposed to P. falciparum, express higher levels of CTLA4 and PD1 on their T cells than uninfected or unexposed control subjects [24, [26] [27] [28] . This increased expression has been proposed to be a sign of T cell exhaustion. Indeed, when coinhibitory + T Cells in Malaria receptors are blocked, T cells from patients with Plasmodium vivax malaria produce higher cytokine levels in response to parasite antigens [28] . However, whether these receptors induce a similar downregulation of the T cell response to P. falciparum malaria had not been addressed so far. Our study showed that during acute P. falciparum malaria, high numbers of CD4 + T cells expressed CTLA4 and PD1 and mostly coexpressed both receptors. Although both, CTLA4 and PD1, are rapidly upregulated after T cell receptor-mediated activation, their expression can also be upregulated by alternative cytokine-based mechanisms [34, 35] . While clearly the vast majority of P. falciparum-specific T cells in our study were CTLA4 + and PD1 (Fig 1D) . Thus, a correlation between CTLA4 and PD1 expression and complete parasite biomass or peak parasitemia cannot fully be excluded. Interestingly, a study by Schlotmann et al. detected a correlation between CTLA4 expression and peak parasitemia (but not parasitemia at time of diagnosis) in adult patients with acute malaria [26] . However, it is also conceivable that the lack of correlation between parasitemia and CTLA4 and PD1 expression in our study reflects the fact that the parasite-induced upregulation of coinhibitor expression is readily saturated by antigen-load and cannot be further increased by higher parasitemia. Other factors such as the duration of antigen exposure or cytokine levels might additionally influence the CTLA4 and PD1 expression in malaria.
To date, several studies have reported that T cell responses to plasmodial and other antigens are reduced during acute malaria and recover after treatment and convalescence [41] [42] [43] [44] [45] . Several mechanisms underlying this phenomenon have been proposed, including impairment of antigen-presenting cell function, the production of anti-inflammatory cytokines, and the induction of apoptosis [45, 46] . Similarly, we found in our study that only 40% of our patients showed measurable T cell proliferation and 65% produced cytokines (predominantly IFNγ and IL10) by intracellular staining in response to P. falciparum, respectively. We propose that the strong induction of CTLA4 and PD1 contributes to the reduced effector function of P. falciparum-specific T cells during acute malaria. Blocking both, CTLA4 and PDL1, enhanced the T cell proliferation in 4 of 11 malaria patients. The blockade showed a stronger effect on cytokine production and increased the malaria-specific IFNγ and IL10 production of all patients who exhibited a cytokine response to P. falciparum and demarcated a positive IFNγ response in one patient who was priorly unresponsive. Our results corroborate observations by us and other groups in rodent malaria models that administration of antibodies against CTLA4 and/or 
IL10
+ effector-like T cells with regulatory function in the blood of healthy volunteers [62] .
Similar to our study, these cells express high levels of PD1 and CTLA4 and low levels of CD127 and respond to persisting antigens such as Candida and CMV but not to vaccine antigens. However, the suppressive activity of these IFNγ [33, 63] . Interestingly, a study by Che et al. showed that naïve T cells failed to expand in vitro in the presence of HIV-primed T cells, and that this suppressive effect was also dependent on T-T cell contact [66] . While peripheral control of inflammation has generally been attributed to adaptive Tr1 cells, which are thought to be a distinct lineage, our observations raise the intriguing hypothesis that during an acute infection, regulatory function is transiently acquired by T eff cells to control the T cell response by three mechanisms: a) autoregulation of the T eff response through upregulation of CTLA4 and PD1 which inhibit cytokine production b) cytokine switch from IFNγ to IL10 production and c) cell-extrinsic inhibition of the T cell proliferation.
This possibility is potentially exciting given the increasing focus on immune-modulating therapies in the last few years that has led to the licensing of antibodies against coinhibitory receptors and the first trials on the transfer of T cell populations [67, 68] + T eff cells play a crucial role in the immune regulation:
they arise from Th1 effector cells and acquire a suppressive phenotype, by expressing coinhibitory receptors, switching to IL10 production and by cell-extrinsic suppression of other T cells. Such a negative feedback loop is probably not unique for P. falciparum malaria and could be a common autoregulatory mechanism that serves to control overwhelming Th1 responses and prevent immunopathology in acute infections.
Materials and Methods

Study population
In total, 25 patients with acute malaria were enrolled during their inpatient treatment at the University Hospital Eppendorf in Hamburg between the first and sixth day of the treatment.
Patients were enrolled consecutively between March 2013 and September 2014. The clinical characteristics of the enrolled patients are summarized in S1 Table. The majority of these patients (14 of 25) were of West African origin and had been living in Germany for !5 years (5-20 years). 8 of the remaining patients were Germans who were infected during vacation or short-term work assignments in a malaria endemic country. Two were German expatriates, living in Western Africa and one patient from Gambia was visiting Germany on vacation.
Patients of West African origin had suffered from repeated malaria episodes as children but had not been diagnosed with malaria > 5 years. The 25 enrolled patients were on average 42 (range 18-70) years old. All had microscopically detectable parasitemia and five had severe malaria, according to the definitions of the WHO [69] . Of the five patients with severe malaria, three suffered from cerebral malaria and two were diagnosed with hyperparasit emia. Patients with cerebral malaria were treated with Artesunate iv, followed by atovaquone-proguanil. All other patients were treated with artesiminin-combination therapy (dihydroartemisin-piperaquin) or atovaquone-proguanil p.o.. Between 5 and 50 ml of heparinized blood was collected from each malaria patient and used for flow cytometric analysis and functional assays. Due to limitations on number of cells, only a subset of functional assays and/or flow cytometric staining could be carried out for each blood sample. In addition to the enrolled patients, anonymous blood samples (1 ml each) from 15 adult patients with an active P. falciparum infection were obtained from the clinical diagnostic lab of the Bernhard Nocht Institute of Tropical Medicine. Baseline information such as age, parasitemia and presentation of symptoms were available for these patients. The latter samples were only subjected to ex vivo flow cytometric T cell analysis (Fig 1B, 1C and 1E ). For a small number of patients, additional follow-up samples were received during treatment via the diagnostic lab and used for ex vivo flow cytometric T cell phenotyping. The 19 control subjects were healthy adult staff members of the Bernhard Nocht Institute of Tropical Medicine and the University Medical Centre Hamburg Eppendorf.
Determination of P. falciparum infection
P. falciparum infection was determined microscopically by experienced lab technicians at the Bernhard Nocht Institute of Tropical Medicine. Thick and thin blood smears were stained with 4% Giemsa and examined under oil immersion (original magnification × 100). Ex vivo staining for immunophenotypic analysis was conducted on fresh whole blood samples from malaria patients and healthy volunteers. For malaria patients, samples were included on the day of diagnosis (day 1) prior to treatment whenever available. Alternatively, the first blood sample obtained from that specific patient was included for flow cytometric analysis. Thus, 100 μl of fresh whole blood was incubated for 30 min at 4°C with the following antibodies: CD4 BV510 (clone OKT4), CD8 AF700 (RPA-T8), CD14 AF 700 (HCD14), CD19 BV510 (HIB19), CD11c PECy7 (Bu15), CD45RA FITC (HI100), CCR7 PECy7 (G043H7), PD1 PerCP Cy5.5 (EH12.2H7), BTLA Biotin (MIH26) with Streptavidin-BV 421, CD25 PE Cy7 (BC96), CD127 BV 421 (A019D5), PD-L1 APC (29E.2A3), PD-L2PE (24F.10C12), CD80 BV 421 (2D10), and CD86 AF488 (IT2.2) (all from BioLegend). Thereafter, the blood samples were lysed and fixed using a Lysis/Fixation buffer (BioLegend), and washed. Subsequent intracellular staining for CTLA4 PE (L3D10), Foxp3 AF647 (259D), Tbet APC (4B19), Granzyme B AF647 (GB11), CD3 APC Cy7 (SK7) (all from BioLegend), and Ki67 AF 488 (MK167) (eBioscience) was conducted using the eBioscience Foxp3/Transcription factor staining buffer set according to the manufacturer's protocol. The flow cytometric data were collected on a LSR II Cytometer (4 laser, Becton Dickinson) and analyzed using FlowJo software (Treestar). Compensations were set using single stained/unstained beads. At least 100 000 cells were collected in the lymphocyte gate. Cells were first gated on forward/sideward scatter to exclude cell debris and gates were set for lymphocytes and monocytes. T cells were then gated on the basis of the lineage markers CD3, CD4 and CD8. Monocytes/macrophages were defined as CD14 define subsequent gates for coinhibitory receptors and ligands and regulatory, memory, and activation markers. FMO is a staining control that includes all antibodies used in a flow cytometric assay except for one fluorochrome of interest (termed FMO) to control for the contribution of spectral overlap to the background when using multiple fluorochromes [70, 71] .
Antigens and mitogens
In vitro P. falciparum antigen-specific CD4 + T cell proliferation and cytokine expression were measured using P. falciparum-infected red blood cells (iRBC) as the antigen. For this, P. falciparum cultures (strain 3D7) were maintained in 0 + erythrocytes in RPMI-1640 medium supplemented with 0.5% AlbuMAX II (Invitrogen) at 37°C according to standard methods [72] . Schizont and late trophozoite stage parasites were isolated magnetically using the Miltenyi LD column. The percentage of infected erythrocytes after magnetic isolation was typically 80-90%. The iRBC were stored in PBS at -70°C until use in cell culture at two iRBC per T cell/PBMC. Uninfected red blood cells (uRBC), namely, the 0 + erythrocytes from the same donors that were used for the parasite cultures, served as negative controls at two uRBC per T cell/PBMC. CMV pp65 protein (Miltenyi, 1 μl/ml) and tetanus toxoid (10 μg/ml) served as alternative antigens. For polyclonal stimulation in proliferation assays, 1 μg/ml soluble anti-CD3 (clone UCHT1, eBioscience) and 1 μg/ml anti-CD28 (clone CD28.2., eBioscience) were used. Alternatively, anti-CD3/28-coated beads (Dynal T cell expander) were used at a ratio of five cells/bead. PHA (Sigma-Aldrich at 5 μg/ml) or PMA/Ionomycin (50ng/500ng) served as the positive controls for intracellular cytokine staining.
Cell isolation and sorting
PBMC were isolated from heparinized whole blood within 2 hours of collection by standard density gradient centrifugation with Ficoll Paque (GE Healthcare) using the SepMate System (Stemcell technologies) according to the manufacturer's instructions. The isolated PBMC were then directly subjected to antigen/mitogen stimulation assays that measured cell proliferation and cytokine production by intracellular staining or underwent further T cell isolation steps. For cell cultures, fresh PBMC were resuspended in complete RPMI (cRPMI), consisting of RPMI 1640 (PAA laboratories) supplemented with 10% pooled human AB serum (SigmaAldrich), 4 mM L-glutamine, 25 mM HEPES, and 80 mg/ml gentamicin (both PAA laboratories). For isolation of T cell subsets, freshly isolated PBMC were washed and resuspended in MACS buffer (PBS with 0.5% BSA and 2 mmol/l EDTA). The PBMC were then negatively selected for CD4 + T cells using the CD4 + T cell isolation kit from Miltenyi according to the manufacturer's protocol. The isolated CD4 + T cell preparations were routinely >90% pure.
An aliquot of each CD4 + T cell preparation was set aside for cell culture. The remaining CD4 + T cells were resuspended in PBS supplemented with 1% human AB serum and surface-stained with anti-CD4 APC (RPA-T4), anti-CD25 PECy7 (BC96), anti-CD127 AF 488 (A019D5), anti-PD1 PerCP Cy5.5 (EH12.2H7), and anti-CTLA4 PE (L3D10). Gates were set based on FMO controls. Natural T regs were first excluded on the basis of high expression of CD25 and low expression of CD127. The remaining CD4 + T cells were then sorted into PD1 + CD4 + T cells and PD1 neg CD4 + T cells. The PD1 + T cell fractions were 50-95% pure for PD1 and CTLA4 after conducting intracellular staining for CTLA4 (S10 Fig) . The CD4 -cells that were acquired in the magnetic-bead sorting step were irradiated with 3000 rad and served as antigen-presenting cells. After isolation, the cells were resuspended in cRPMI and used for cell culture.
Cell culture and suppression assays
Freshly isolated PBMC or T cells were cultured in round-bottom 96-well plates directly after isolation. To assess antigen-specific responsiveness of PBMC, the cells were cultured at 1×10 6 / ml for 120 hours with 2 iRBC or uRBC/cell, after which 80 μl of supernatant was removed for cytokine detection assays. To assess whether blocking the ligation of PDL1 and CTLA4 would enhance the proliferation and cytokine production of these PBMC, the cells were coincubated with 10 μg/ml anti-PDL1 (MIH1, eBioscience) and 10 μg/ml anti-CTLA4 (Ipilimumab natant was removed for cytokine detection assays. Lymphocyte proliferation in the PBMC and suppression assays was determined by pulsing the cultures after 120 hours with 1 μCi/ml 3 H-Thymidine for 18 hours, harvesting the cells onto cellulose filters, and measuring radiolabeled thymidine incorporation by scintillation counting. The results were expressed as counts per minute (cpm). A stimulation index >2 (mean cpm of stimulated cells/mean cpm of unstimulated cells) was considered to be a positive proliferative response. To determine the suppressive mechanism, the suppression cultures were co-cultured with anti-PDL1 (MIH1, eBioscience), anti-CTLA4 (Ipilimumab), anti-TGFβ (1D11.16.8, eBioscience), and anti-IL10R (3F9, BioLegend) (all at 10 μg/ml). Transwell experiments were conducted using Nunc transwell inserts. Cell culture conditions were set up in triplicates when sufficient cell numbers were available. However, limitations in cell numbers meant that not all samples could be subjected to all experimental conditions.
CFSE proliferation assay
Freshly isolated PBMC were labeled with 15 mM CFSE (Molecular Probes) and cultured with iRBC, uRBC or medium (negative controls), or anti-CD3/28 (positive control), harvested after 72 hours, surface-stained for CD4, CD8, CD3 and PD1, and intracellularly stained for CTLA4 using the eBioscience Foxp3/Transcription factor staining buffer. Dead cells were excluded using the UV live/dead stain (Life Technologies).
Intracellular staining for cytokines
To detect intracellular cytokines, PBMC were cultured at 10 6 cells/ml and stimulated with iRBC, uRBC, PHA, anti-CD3/28, CMV or without antigen for 18 hours. Brefeldin A and Monensin (1 μl/ml each, both from BioLegend) were added after 6 hours of culture. For control cultures with PMA/Ionomycin, PBMC were stimulated with 50ng PMA and 500ng Ionomycin for a total duration of 12h. The cells were then washed and surface-stained with the following antibodies: CD4 BV 510, CD8 AF 700, PD1 PerCP Cy5.5, and CD127 BV 421. To detect dead cells, the cells were also stained with UV live/dead (Life Technologies). The cells were then fixed and permeabilized using the eBioscience Foxp3 /Transcription factor staining buffer set and intracellularly stained using the following antibodies: IFNγ FITC (4S.B3), IL10PE (JES3-9D7), IL4BV 421 (MP4-25D2), TNFα PECy7 (MAB11), IL13PE (JES10-5A2), CTLA4 PE (L3D10), Foxp3 AF 647 (259D), CD3 APC Cy7 (SK7) and Tbet APC (4B19). Samples were acquired on a LSR II and analyzed using FlowJo software. Gates were set on the basis of FMO controls.
Quantification of cytokines in culture supernatants
Cultural supernatants were harvested after 120 hours and frozen at -20°C. The cytokines IFNγ and IL10 were measured using the eBioscience ELISA ready-SET-go kit according to the manufacturer's recommendations. The detection limits were 10 pg/ml for IL10 and 20 pg/ml for IFNγ. For statistical analysis, samples with optical density readings below the limit of the standard curve of the assay were assigned a value half that of the detection level.
Statistics
Two groups were compared using the student's t-test. For comparison of several parameters between two groups, t-tests with Holm-Sidak correction for multiple comparisons were used (Graph Pad Prism 7). Three or more groups were compared by ANOVA with the Bonferroni post hoc test. For data that was not normally distributed, the Wilcoxon matched pairs test or Friedman test with Dunn´s multiple comparison test was used. Correlation analysis was conducted by calculating Pearson's product-moment correlation coefficient. IFNγ/IL10 cytokine combinations displayed in pie charts were compared between the two groups by performing a partial permutation test in SPICE [73] .
Study approval
Ethical approval was obtained from the Ethikkommission Hamburg. Written informed consent was obtained from all enrolled participants prior to inclusion in the study. 
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